AzTrials
AzTrials

GliomaMicroECoGGNCT06408428

Glioma Intraoperative MicroElectroCorticoGraphy

A study testing PANAXIUM MicroECoG in people with Glioma and Epilepsy, run by Institut National de la Santé Et de la Recherche Médicale, France at 3 sites in France.

Not yet recruiting

Opening soon. The study is approved but enrolment has not started yet. Sites may already take enquiries.

Sites and contacts
Official record
Search all trials

Trial summary

The goal of this clinical trial is to validate the safety and to assess the quality of the signals provided by newly developed micro ElectroCorticoGraphy electrodes, provided by the company Panaxium, based on conductive polymers (PEDOT:PSS) in patients suffering of gliomas during resection surgery performed in awake… Read more about this study

Who is it for?
Ages 18 years and older
Conditions the study is for
Glioma, Epilepsy
What is being tested?
PANAXIUM MicroECoG
Type of treatment
Medical device
Could I receive a placebo?
No, everyone receives an active treatment
How many people
50 participants
Where
3 sitesFrance
Study dates
Sep 2025to Mar 2028
Phase
Interventional
Are there results?
Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Patients suffering of a diffuse cerebral glioma for which surgical resection is indicated.
  • Planned awake surgery with intraoperative functional mapping.
  • Planned surgery with ECoG electrophysiological monitoring.
  • Age greater than or equal to 18 years.
  • Enrolled in a social security scheme, Couverture Médicale Universelle (CMU) or equivalent.
  • Have given written consent.

Who cannot join

  • Acute or untreated infection (viral, bacterial or fungal).
  • Current treatment with antibiotics.
  • Pregnant or breast-feeding women.
  • Other pathologies that could interfere with the neurological evaluation or compromise the subject's safety.
  • Participation in therapeutic biomedical research that could modify the lesion or its environment during the study period (whether by drug or medical device) or subject to an exclusion period for other research.
  • Adult subject to legal protection

Trial locations and contacts

3 sites in 1 country. Contact the study team or a site near you to ask about taking part.

Gilles Huberfeld, MD, PhD contact

+331 40 78 92 87

gilles.huberfeld@inserm.fr

France3 sites
  • Hôpital Pitié Salpêtrière

    Paris, 75013

    Bertrand MATHON, PhD

    Bertrand MATHON, PhD

  • Centre Hospitalier Sainte-Anne

    Paris, 75014

    Johan PALLUD, PhD, J.PALLUD@ghu-paris.fr

    Johan PALLUD, PhD

  • Hôpital Fondation Adolphe de Rothschild

    Paris, 75019

    Gilles HUBERFELD, PhD, ghuberfeld@for.paris

    Gilles HUBERFELD, PhD

Other trials in France

About this study

The goal of this clinical trial is to validate the safety and to assess the quality of the signals provided by newly developed micro ElectroCorticoGraphy electrodes, provided by the company Panaxium, based on conductive polymers (PEDOT:PSS) in patients suffering of gliomas during resection surgery performed in awake condition. The main questions it aims to answer are:

  • Safety of PEDOT:PSS microECoGs by assessing the rate of serious adverse events associated with their use during glioma surgery.
  • Quality of PEDOT:PSS microECoGs recordings, as compared with recordings with traditional macroelectrodes, assessed by signal-to-noise ratio, impedance, ability to detect ripples (100-250 Hz) and fast ripples (250-600 Hz), ability to record epileptic activity (spikes and equivalent) either spontaneously or following direct electrical stimulation (afterdischarges).
  • Practicality of microelectrodes use as perceived by neurosurgeons.
  • Exploratory objectives: ability to record multi-unit activity, correlation between microECoG activity and tumor infiltration - local oncometabolite concentrations, determination of epileptic seizure rate during electrode use.

Participants will be recorded during awake glioma surgery by the newly developed micro ElectroCorticoGraphy electrodes and by routine macroelectrodes, as standard of care during both mapping of cortical activities and electrical stimulations used to assess the functional mapping mandatory for tailored tumor resection.

Read the detailed description

Electroencephalography (EEG) is a widely-used tool for studying brain activity, developed in humans in the late 1920s. Its indications have evolved as brain imaging techniques have developed, but it remains extremely useful in the fields of epileptology, comas, brain death, post-anoxic, metabolic, toxic encephalopathies and encephalitis. Alongside scalp EEG, intracranial recordings have been developed to optimize the localization of epileptic activity, with a view to epilepsy surgery.

Two main categories of intracranial electrodes are currently in use.

  1. StereoElectroEncephalopGraphy electrodes consist of a stylus with a string of cylindrical contacts along its length, implanted directly into the brain parenchyma.
  2. ElectroCorticoGraphy (ECoG) electrodes, non-penetrating, organized in strips or grids of 4 to 64 electrodes, disc-shaped, 0.2 to 1 cm in diameter, 0.5 to 1 mm thick, used to collect cerebral activity at the cortical surface.

Among its indication, surgery is a favorable circumstance for using ECoG. During brain surgery, cortical exposure enables cortical EEG recording without additional invasiveness. Intraoperative ECoG is of particular interest in epilepsy surgery, recently reactivated by the discovery of better electrophysiological biomarkers. In glioma surgery, often performed under awake conditions, cortical recording helps to establish a functional cerebral map and to adapt the resection. Indeed, ECoG recordings can be performed during awake surgery, without any disturbance of neuronal activity by anesthesia, to map epileptic activity (using visual identification of spikes) and to look for seizures induced by electrical stimulation. The evolution of these recording techniques is moving towards the development of tools for automatic analysis and mapping of new biomarkers, more relevant but more difficult to record because they are more focal and characterized by amplitudes close to background noise, such as high-frequency oscillations. New types of cortical electrodes are being developed to improve the spatial resolution (better localization), temporal resolution (faster activity detection) and detection sensitivity (signal-to-noise ratio) of cortical electrical signals.

New electrodes have recently been developed, based on the use of conductive organic polymer coatings such as poly(3,4-ethylenedioxythiophene (PEDOT: PSS), to optimize the signal-to-noise ratio, organized in electrode arrays that are 100 times thinner (5 microns vs. 0.5 mm for standard electrodes), 250 times smaller (between 30 and 500 microns vs. 8 mm for standard electrodes) and with more electrodes (128 vs. 6 or 8 for standard electrodes). This type of electrode, known as microECoG, has been validated in animals and has already been used in human research for intraoperative cortical recordings. They enable us to improve the quality of the recorded signal and to go down to a new scale, at the level of the neuron. Moreover, the very low thickness of the electrodes improves their conformability to the cortex, making them much more tolerable and enabling extended recordings to be envisaged as part of future man/machine interfaces.

The French company Panaxium is developing microECoG electrodes. As part of a collaborative project, Panaxium have designed a 4x2 cm, 6 micron-thick electrode comprising 128 electrodes (28 500 µm electrodes, 96 30 µm diameter microelectrodes organized as tetrodes and 4 reference electrodes) for clinical use in humans. The aim of this study is to explore the safety and quality of signals collected by the Panaxium microECoG during awake surgery for brain gliomas. Recording will be carried out using a high-performance EEG system CE-marked for medical use in humans.

The electrode will be placed on the cortical surface and repositioned every 90 seconds to sample the entire exposed brain surface. During the cortical electrical stimulation mapping phase, the electrode will be left at the edge of the field to detect epileptic discharges induced by stimulation. After resection, a new recording of the residual cortical surface will be made to check for persistent electrical anomalies. The surgeries and recordings will be carried out in 3 centers by neurosurgeons with expertise in brain tumors and awake surgery: Hôpital Sainte-Anne/GHU Paris), Hôpital Pietié-Salpêtrière, Hopital Fondation Adolphe de Rostschild. In the last 10 patients, the Panaxium microECoG will be compared with a macro-electrode for clinical use.

The primary endpoint will be the incidence of Serious Adverse Events due to the use of Panaxium microelectrodes during surgery and the following four days: cortical lesion by the electrode, infection, bleeding, aseptic meningitis, neurological deficit due to the use of the electrode, death. Secondary evaluation criteria will be the quality of recordings enabled by the Panaxium microECoG (signal-to-noise ratio reflecting signal quality, electrode impedance during surgery reflecting technical quality, detection of fast ripple (100-250 Hz) and fast ripple (250-600 Hz) oscillations), only possible with high-performance recorders, ability to record spontaneous epileptic activity (spikes and equivalent) or direct post-electrical stimulation (post-discharges)) and practicality of use as perceived by neurosurgeons. Finally, as an exploratory study for future uses of these electrodes, we will investigate their ability to record multi-unit activity (action potentials from single neurons) and the correlation between recorded activity and tumor infiltration, as well as local oncometabolite concentration.

Conditions
Glioma, Epilepsy
Being tested
PANAXIUM MicroECoG
Keywords
Glioma surgery, Awake surgery, MicroElectroCorticoGraphy, EEG
Medical subject headings
Glioma, Epilepsy

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • PANAXIUM MicroECoGDevice

    The PANAXIUM microelectrode ( 4x2 cm, 6 micron-thick electrode comprising 128 electrodes (28 500 µm electrodes, 96 30 µm diameter microelectrodes organized as tetrodes and 4 reference electrodes) will be placed on the cortical surface and repositioned every 90 seconds to sample the entire exposed brain surface. During the cortical electrical stimulation mapping phase, the electrode will be left at the edge of the field to detect epileptic discharges induced by stimulation. After resection, a new recording of the residual cortical surface will be made to check for persistent electrical anomalies. In the last 10 patients, the Panaxium microECoG will be compared with a macro-electrode for clinical use.

Study groups in NCT06408428
Study groupRoleWhat they receive
Glioma Surgery - MicroECoG recordingExperimentalNot described
Receives: Device: PANAXIUM MicroECoG

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Safety of PEDOT:PSS microECoGs use

    Assessment of the safety of PEDOT:PSS microECoGs use by assessing the rate of serious adverse events associated with their use during glioma surgery

    Measured: 30 months

Secondary outcomes (2)
  1. Quality of PEDOT:PSS microECoGs recordings

    Quality of PEDOT:PSS microECoGs recordings assessment by signal-to-noise ratio, impedance, ability to detect ripples (100-250 Hz) and fast ripples (250-600 Hz), ability to record epileptic activity (spikes and equivalent) either spontaneously or following direct electrical stimulation (afterdischarges)

    Measured: 30 months

  2. Practicality of microelectrodes use as perceived by neurosurgeons.

    Practicality of microelectrodes use as perceived by neurosurgeons.

    Measured: 30 months

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted10 May 2024
  2. Study startSep 2025 (estimated)
  3. Primary completionSep 2027 (estimated)
  4. Study completionMar 2028 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Device feasibility
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrolment
50 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT06408428
Sponsor's protocol ID
C20-90
Acronym
MicroECoGG
Status last verified
Mar 2025
First submitted
23 Jan 2024
Last updated
12 Mar 2025
Results posted
No
Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No

Questions about this trial

What is this clinical trial studying?

A study testing PANAXIUM MicroECoG in people with Glioma and Epilepsy, run by Institut National de la Santé Et de la Recherche Médicale, France at 3 sites in France.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 6 inclusion and 6 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: opening soon, as of the sponsor's last update on 12 Mar 2025. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 3 sites in France. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

Contact Gilles Huberfeld, MD, PhD (+331 40 78 92 87, gilles.huberfeld@inserm.fr), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Safety of PEDOT:PSS microECoGs use (time frame: 30 months). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 12 Mar 2025; AzTrials last refreshed its copy on 30 Oct 2026.

Free account

Keep searching with a free account

You’ve used your 3 free searches for this session. Log in or create a free AzTrials account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in